Human Longevity, Inc. Supports Medical Innovation to Advance the Treatment of Cancer and Other Diseases

HLI Co-Founder, Robert Hariri Speaks on Medical Innovation at 2014 BIO International Convention in San Diego

Jun 25, 2014, 11:10 ET from Human Longevity, Inc.

LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, today called on physicians, the insurance industry and political leaders to support promising new avenues of medical discovery on behalf of patients with life-threatening diseases including cancer.

HLI is dedicated to changing the practice of healthcare and to positively impacting aging and age-related diseases using advances in genomics and stem cell therapies. The company is building the largest human genome sequencing operation in the world to compile the most comprehensive human genotype, microbiome, and phenotype database available to tackle the diseases associated with aging-related human biological decline. HLI's co-founders are: Robert Hariri, MD, Ph.D., stem cell pioneer; J. Craig Venter, Ph.D., biologist and genomics leader; and Peter Diamandis, M.D., Chairman and CEO of the XPRIZE Foundation.

"Today people with cancer must wage war on two fronts, battling their disease and fighting for advanced treatments," said Dr. Hariri. "The oncology field is changing rapidly. Every tumor is different and every patient is different.  HLI believes the time is now to incorporate every individual's genetic code as the starting point of care and therapeutic development." 

The value of innovation in healthcare is well-documented.  A report in the journal, Clinical Cancer Research states that continued support for science and innovation could avert a predicted crisis in health spending in oncology just as it has in other major public health problems, such as HIV/AIDS.

Dr. Hariri, HLI co-founder and the Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, speaks at BIO 2014 in San Diego this week on how medical innovation in the fields of cancer and stem cell therapeutics can save money and save lives. HLI plans to work closely with the Value of Medial Innovation ( and in a project called MY LIFE IS WORTH IT. This new online initiative was launched recently to give patients a voice in discussions about the value of the very treatments that will affect their own lives. More information about this program can be found at

About Human Longevity, Inc.
HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit,

Logo -

SOURCE Human Longevity, Inc.